OBJECTIVE: Resistin is associated with inflammation and insulin resistance and exerts direct effects on myocardial cells including hypertrophy and altered contraction. We investigated the association of serum resistin concentrations with risk for incident heart failure (HF) in humans. METHODS AND RESULTS: We studied 2902 older persons without prevalent HF (age, 73.6+/-2.9 years; 48.1% men; 58.8% white) enrolled in the Health, Aging, and Body Composition (Health ABC) Study. Correlation between baseline serum resistin concentrations (20.3+/-10.0 ng/mL) and clinical variables, biochemistry panel, markers of inflammation and insulin resistance, adipocytokines, and measures of adiposity was weak (all rho <0.25). During a median follow-up of 9.4 years, 341 participants (11.8%) developed HF. Resistin was strongly associated with risk for incident HF in Cox proportional hazards models controlling for clinical variables, biomarkers, and measures of adiposity (HR, 1.15 per 10.0 ng/mL in adjusted model; 95% CI, 1.05 to 1.27; P=0.003). Results were comparable across sex, race, diabetes mellitus, and prevalent and incident coronary heart disease subgroups. In participants with available left ventricular ejection fraction at HF diagnosis (265 of 341; 77.7%), association of resistin with HF risk was comparable for cases with reduced versus preserved ejection fraction. CONCLUSIONS: Serum resistin concentrations are independently associated with risk for incident HF in older persons.
OBJECTIVE:Resistin is associated with inflammation and insulin resistance and exerts direct effects on myocardial cells including hypertrophy and altered contraction. We investigated the association of serum resistin concentrations with risk for incident heart failure (HF) in humans. METHODS AND RESULTS: We studied 2902 older persons without prevalent HF (age, 73.6+/-2.9 years; 48.1% men; 58.8% white) enrolled in the Health, Aging, and Body Composition (Health ABC) Study. Correlation between baseline serum resistin concentrations (20.3+/-10.0 ng/mL) and clinical variables, biochemistry panel, markers of inflammation and insulin resistance, adipocytokines, and measures of adiposity was weak (all rho <0.25). During a median follow-up of 9.4 years, 341 participants (11.8%) developed HF. Resistin was strongly associated with risk for incident HF in Cox proportional hazards models controlling for clinical variables, biomarkers, and measures of adiposity (HR, 1.15 per 10.0 ng/mL in adjusted model; 95% CI, 1.05 to 1.27; P=0.003). Results were comparable across sex, race, diabetes mellitus, and prevalent and incident coronary heart disease subgroups. In participants with available left ventricular ejection fraction at HF diagnosis (265 of 341; 77.7%), association of resistin with HF risk was comparable for cases with reduced versus preserved ejection fraction. CONCLUSIONS: Serum resistin concentrations are independently associated with risk for incident HF in older persons.
Authors: Muredach P Reilly; Michael Lehrke; Megan L Wolfe; Anand Rohatgi; Mitchell A Lazar; Daniel J Rader Journal: Circulation Date: 2005-02-14 Impact factor: 29.690
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: C M Steppan; S T Bailey; S Bhat; E J Brown; R R Banerjee; C M Wright; H R Patel; R S Ahima; M A Lazar Journal: Nature Date: 2001-01-18 Impact factor: 49.962
Authors: Matteo Cesari; Brenda W J H Penninx; Anne B Newman; Stephen B Kritchevsky; Barbara J Nicklas; Kim Sutton-Tyrrell; Susan M Rubin; Jingzhong Ding; Eleanor M Simonsick; Tamara B Harris; Marco Pahor Journal: Circulation Date: 2003-10-20 Impact factor: 29.690
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino Journal: Circulation Date: 2003-03-25 Impact factor: 29.690
Authors: Evan D Muse; David I Feldman; Michael J Blaha; Zeina A Dardari; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir; Michael H Criqui; Mary Cushman; Robyn L McClelland; Matthew A Allison Journal: Atherosclerosis Date: 2014-12-23 Impact factor: 5.162
Authors: Vishal N Rao; Di Zhao; Matthew A Allison; Eliseo Guallar; Kavita Sharma; Michael H Criqui; Mary Cushman; Roger S Blumenthal; Erin D Michos Journal: JACC Heart Fail Date: 2018-10-10 Impact factor: 12.035
Authors: Baris Gencer; Reto Auer; Nathalie de Rekeneire; Javed Butler; Andreas Kalogeropoulos; Douglas C Bauer; Stephen B Kritchevsky; Iva Miljkovic; Eric Vittinghoff; Tamara Harris; Nicolas Rodondi Journal: Atherosclerosis Date: 2015-12-09 Impact factor: 5.162
Authors: Qibin Qi; Claudia Menzaghi; Shelly Smith; Liming Liang; Nathalie de Rekeneire; Melissa E Garcia; Kurt K Lohman; Iva Miljkovic; Elsa S Strotmeyer; Steve R Cummings; Alka M Kanaya; Frances A Tylavsky; Suzanne Satterfield; Jingzhong Ding; Eric B Rimm; Vincenzo Trischitta; Frank B Hu; Yongmei Liu; Lu Qi Journal: Hum Mol Genet Date: 2012-07-26 Impact factor: 6.150